Anti TDP-43, phospho Ser409/410

TDP-43, a heterogeneous nuclear ribonucleoprotein, was identified as a component of ubiquitin-positive and tau-negative inclusions observed in cases of frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). Immunochemical analyses using antibodies generated against phospho- and non-phosphopeptides of human TDP-43 revealed that abnormally phosphorylated full-length TDP-43 (45 kDa), C-terminal fragments (~25 kDa) and smearing substances are deposited as intracellular inclusions in affected regions of FTLD-U and ALS cases.

This antibody is a powerful tool for biochemical and immunohistochemical analyses of neurodegenerative diseases and for evaluation of cellular or animal models of TDP-43 proteinopathy.

Specifications
Important Notice About Format Change:
Replacement for Cat No.: CAC-TIP-PTD-M01
For lots "11-9-20" and newer, this antibody is now provided as ammonium sulfate precipitated culture supernate, formulated in 50% glycerol, 0.05% NaN3. Older lots were provided as raw culture supernate. Vials of the previous format remain available while supplies last. (posted: March 2020). This has improved sensitivity, and does not require altering current protocols.

Recommended dilutions:

• Western blotting:1/1000-1/3000
• Immunohistochemistry: 1/3000-1/10000
• ELISA: 1/1000-1/5000
• Other applications not tested
• Optimal dilutions/concentrations should be determined by end user.

References

1. 1. Inukai Y, Nonaka T, Arai T, et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett. 582, 2899-2904, 2008 PubMed: 18656473